These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35285080)

  • 1. Duodenal-jejunal bypass liner for the treatment of type 2 diabetes and obesity: 3-year outcomes in the First National Health Service (NHS) EndoBarrier Service.
    Ryder REJ; Yadagiri M; Burbridge W; Irwin SP; Gandhi H; Bashir T; Allden RA; Wyres M; Cull M; Bleasdale JP; Fogden EN; Anderson MR; Sen Gupta P
    Diabet Med; 2022 Jul; 39(7):e14827. PubMed ID: 35285080
    [No Abstract]   [Full Text] [Related]  

  • 2. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study.
    Betzel B; Homan J; Aarts EO; Janssen IMC; de Boer H; Wahab PJ; Groenen MJM; Berends FJ
    Surg Endosc; 2017 Jul; 31(7):2881-2891. PubMed ID: 27804045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised controlled trial of a duodenal-jejunal bypass sleeve device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes mellitus.
    Glaysher MA; Mohanaruban A; Prechtl CG; Goldstone AP; Miras AD; Lord J; Chhina N; Falaschetti E; Johnson NA; Al-Najim W; Smith C; Li JV; Patel M; Ahmed AR; Moore M; Poulter N; Bloom S; Darzi A; Le Roux C; Byrne JP; Teare JP
    BMJ Open; 2017 Nov; 7(11):e018598. PubMed ID: 29146657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide.
    Ryder REJ; Laubner K; Benes M; Haluzik M; Munro L; Frydenberg H; Teare JP; Ruban A; Fishman S; Santo E; Stengel R; De Jonge C; Greve JW; Cohen RV; Aboud CM; Holtmann GJ; Rich G; McMaster JJ; Battelino T; Kotnik P; Byrne JP; Mason JC; Bessell J; Bascomb J; Kow L; Collins J; Chisholm J; Pferschy PN; Sourij H; Cull ML; Wyres MC; Drummond R; McGowan B; Amiel SA; Yadagiri M; Sen Gupta P; Aberle J; Seufert J
    Diabetes Care; 2023 Apr; 46(4):e89-e91. PubMed ID: 36716004
    [No Abstract]   [Full Text] [Related]  

  • 5. Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34 kg/m2: a report of 2 cases.
    Cohen RV; Schiavon CA; Pinheiro JS; Correa JL; Rubino F
    Surg Obes Relat Dis; 2007; 3(2):195-7. PubMed ID: 17386401
    [No Abstract]   [Full Text] [Related]  

  • 6. Is reimplantation of the duodenal-jejunal bypass liner feasible?
    Koehestanie P; Betzel B; Aarts EO; Janssen IM; Wahab P; Berends FJ
    Surg Obes Relat Dis; 2015; 11(5):1099-104. PubMed ID: 25979208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The duodenal-jejunal bypass sleeve (EndoBarrier Gastrointestinal Liner) for weight loss and treatment of type 2 diabetes.
    Patel SR; Hakim D; Mason J; Hakim N
    Surg Obes Relat Dis; 2013; 9(3):482-4. PubMed ID: 23452926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACP Journal Club: in obesity with type 2 diabetes, duodenal-jejunal bypass liners improved weight loss and HbA1c during treatment.
    Cheskin LJ; Bloomberg School Of Public Health JH; Mullin GE
    Ann Intern Med; 2015 Feb; 162(4):JC9. PubMed ID: 25686196
    [No Abstract]   [Full Text] [Related]  

  • 9. [EndoBarrier as a treatment for obesity and diabetes].
    Greve JWM; Bouvy ND
    Ned Tijdschr Geneeskd; 2018; 162():D2268. PubMed ID: 29519261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse Events of the Duodenal-Jejunal Bypass Liner: a Systematic Review.
    Betzel B; Drenth JPH; Siersema PD
    Obes Surg; 2018 Nov; 28(11):3669-3677. PubMed ID: 30121857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial.
    Koehestanie P; de Jonge C; Berends FJ; Janssen IM; Bouvy ND; Greve JW
    Ann Surg; 2014 Dec; 260(6):984-92. PubMed ID: 25072436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EndoBarrier®: a Safe and Effective Novel Treatment for Obesity and Type 2 Diabetes?
    Patel N; Mohanaruban A; Ashrafian H; Le Roux C; Byrne J; Mason J; Hopkins J; Kelly J; Teare J
    Obes Surg; 2018 Jul; 28(7):1980-1989. PubMed ID: 29450844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute pancreatitis as an adverse event in patients with the duodenal-jejunal bypass liner.
    Betzel B; Homan J; Aarts E; Janssen I; Spanier M; Wahab P; Groenen M; Berends F
    Endoscopy; 2015 Nov; 47(11):1050-3. PubMed ID: 26021308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The duodenal-jejunal bypass liner for the treatment of type 2 diabetes mellitus and/or obesity: a systematic review.
    Zechmeister-Koss I; Huić M; Fischer S;
    Obes Surg; 2014 Feb; 24(2):310-23. PubMed ID: 24293185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [EndoBarrier for counteracting obesity and metabolic syndrome].
    Verdam FJ; Liedorp PR; Geubbels N; Schouten R; Janssen IM; Koek GH; Greve JW
    Ned Tijdschr Geneeskd; 2012; 156(13):A3844. PubMed ID: 22456287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of 6 and 12 months Duodenal-Jejunal Bypass Liner Treatment on Obesity and Type 2 Diabetes: a Crossover Cohort Study.
    van Rijn S; Betzel B; de Jonge C; van Dijk DPJ; Janssen IM; Berends FJ; Bouvy ND; Greve JWM
    Obes Surg; 2018 May; 28(5):1255-1262. PubMed ID: 29110244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical follow-up on weight loss, glycemic control, and safety aspects of 24 months of duodenal-jejunal bypass liner implantation.
    Betzel B; Cooiman MI; Aarts EO; Janssen IMC; Wahab PJ; Groenen MJM; Drenth JPH; Berends FJ
    Surg Endosc; 2020 Jan; 34(1):209-215. PubMed ID: 30877567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effectiveness and Safety of the Duodenal-Jejunal Bypass Liner (DJBL) for the Management of Obesity and Glycaemic Control: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yvamoto EY; de Moura DTH; Proença IM; do Monte Junior ES; Ribeiro IB; Ribas PHBV; Hemerly MC; de Oliveira VL; Sánchez-Luna SA; Bernardo WM; de Moura EGH
    Obes Surg; 2023 Feb; 33(2):585-599. PubMed ID: 36508156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal evaluation of efficacy, safety and nutritional status during one-year treatment with the duodenal-jejunal bypass liner.
    Riedel N; Laubner K; Lautenbach A; Schön G; Schlensak M; Stengel R; Eberl T; Dederichs F; Aberle J; Seufert J
    Surg Obes Relat Dis; 2018 Jun; 14(6):769-779. PubMed ID: 29650340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of duodenal-jejunal bypass liner for obesity and type 2 diabetes: A systematic review and meta-analysis.
    Chen W; Feng J; Dong S; Guo J; Zhou F; Hu S; Hu R; Wang C; Ma Y; Dong Z
    Obes Rev; 2024 Nov; 25(11):e13812. PubMed ID: 39191438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.